Cargando…

Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes. In most cases it develops on a background of liver steatohepatitis, fibrosis, and cirrhosis. Guadecitabine (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jueliger, Simone, Lyons, John, Cannito, Sara, Pata, Illar, Pata, Pille, Shkolnaya, Marianna, Lo Re, Oriana, Peyrou, Marion, Villarroya, Francesc, Pazienza, Valerio, Rappa, Francesca, Cappello, Francesco, Azab, Mohammad, Taverna, Pietro, Vinciguerra, Manlio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094635/ https://www.ncbi.nlm.nih.gov/pubmed/27646854 http://dx.doi.org/10.1080/15592294.2016.1214781

Ejemplares similares

Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies
por: Xu, Cong, et al.
Publicado: (2017)

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
por: Wong, Jonathan, et al.
Publicado: (2022)

Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
por: Papadatos-Pastos, Dionysis, et al.
Publicado: (2022)

Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer
por: Kovacovicova, Kristina, et al.
Publicado: (2018)

Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
por: Covre, Alessia, et al.
Publicado: (2013)

Histone macroH2A1.2 promotes metabolic health and leanness by inhibiting adipogenesis
por: Pazienza, Valerio, et al.
Publicado: (2016)

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
por: Srivastava, Pragya, et al.
Publicado: (2015)

Gut Dysbiosis and Adaptive Immune Response in Diet-induced Obesity vs. Systemic Inflammation
por: Pindjakova, Jana, et al.
Publicado: (2017)

Immunopositivity for Histone MacroH2A1 Isoforms Marks Steatosis-Associated Hepatocellular Carcinoma
por: Rappa, Francesca, et al.
Publicado: (2013)

Correction: Immunopositivity for Histone MacroH2A1 Isoforms Marks Steatosis-Associated Hepatocellular Carcinoma
por: Rappa, Francesca, et al.
Publicado: (2013)

Porcine circovirus type 2 ORF3 protein induces apoptosis in melanoma cells
por: Teras, Marina, et al.
Publicado: (2018)

Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
por: Chung, Woonbok, et al.
Publicado: (2019)

Mutual Antagonism between Circadian Protein Period 2 and Hepatitis C Virus Replication in Hepatocytes
por: Benegiamo, Giorgia, et al.
Publicado: (2013)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma
por: Li, Juan, et al.
Publicado: (2022)

PPARs Signaling and Cancer in the Gastrointestinal System
por: Pazienza, Valerio, et al.
Publicado: (2012)

A potential role of alternative splicing in the regulation of the transcriptional activity of human GLI2 in gonadal tissues
por: Speek, Mart, et al.
Publicado: (2006)

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
por: Albany, Costantine, et al.
Publicado: (2016)

Two New SGI1-LK Variants Found in Proteus mirabilis and Evolution of the SGI1-HKL Group of Salmonella Genomic Islands
por: de Curraize, Claire, et al.
Publicado: (2020)

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
por: Sébert, Marie, et al.
Publicado: (2019)

3rd European Cray/SGI MPP Workshop
Publicado: (1997)

5th European SGI-Cray MPP Workshop
Publicado: (1999)

SGI: automatic clinical subgroup identification in omics datasets
por: Buyukozkan, Mustafa, et al.
Publicado: (2021)

Amphiregulin activates human hepatic stellate cells and is upregulated in non alcoholic steatohepatitis
por: McKee, Chad, et al.
Publicado: (2015)

LINE-1 Hypomethylation in Blood and Tissue Samples as an Epigenetic Marker for Cancer Risk: A Systematic Review and Meta-Analysis
por: Barchitta, Martina, et al.
Publicado: (2014)

Mass balance and metabolite profiling of (14)C-guadecitabine in patients with advanced cancer
por: Roosendaal, Jeroen, et al.
Publicado: (2019)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
por: Darvishi, Emad, et al.
Publicado: (2020)

A Differential Pattern of Batokine Expression in Perivascular Adipose Tissue Depots From Mice
por: Mestres-Arenas, Alberto, et al.
Publicado: (2021)

Deficiency of histone variant macroH2A1.1 is associated with sexually dimorphic obesity in mice
por: Chiodi, Valentina, et al.
Publicado: (2023)

Histone MacroH2A1: A Chromatin Point of Intersection between Fasting, Senescence and Cellular Regeneration
por: Lo Re, Oriana, et al.
Publicado: (2017)

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study
por: Fenaux, Pierre, et al.
Publicado: (2023)

Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
por: Fazio, Carolina, et al.
Publicado: (2018)

Low fruit consumption and folate deficiency are associated with LINE-1 hypomethylation in women of a cancer-free population
por: Agodi, Antonella, et al.
Publicado: (2015)

Erratum for de Curraize et al., “Two New SGI1-LK Variants Found in Proteus mirabilis and Evolution of the SGI1-HKL Group of Salmonella Genomic Islands”
por: de Curraize, Claire, et al.
Publicado: (2020)

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients
por: Tavano, Francesca, et al.
Publicado: (2014)

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer
por: Albany, Costantine, et al.
Publicado: (2020)

Mono-ADP-Ribosylhydrolase MACROD2 Is Dispensable for Murine Responses to Metabolic and Genotoxic Insults
por: Lo Re, Oriana, et al.
Publicado: (2018)

Macro Histone Variants: Emerging Rheostats of Gastrointestinal Cancers
por: Giallongo, Sebastiano, et al.
Publicado: (2019)

DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway
por: Karan, Dev, et al.
Publicado: (2023)

SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial
por: Crabb, Simon, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n3faofd2pv4ksqr0odlb603il3